Stay updated on Psilocybin Safety & Efficacy in TRD - Clinical Trial
Sign up to get notified when there's something new on the Psilocybin Safety & Efficacy in TRD - Clinical Trial page.

Latest updates to the Psilocybin Safety & Efficacy in TRD - Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov page now presents the record for a completed Phase 2 psilocybin study for treatment-resistant depression, including its design, results measures, participating locations, and study documents.SummaryDifference53%

- Check11 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedAn NIH sitewide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appeared, and the site revision changed from v3.7.1 to v3.7.2. The study page continues to display a 403 Forbidden error.SummaryDifference1%

- Check39 days agoChange DetectedThe ClinicalTrials.gov error page’s footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check53 days agoChange DetectedSeveral documents in the Study Documents section have been removed, including the Statistical Analysis Plan and the Study Protocol. This change reduces direct access to the study's methodological details and supporting materials on the page.SummaryDifference17%

- Check60 days agoChange DetectedThe page version was updated from v3.6.6 to v3.7.0, signaling a newer version of the study details page. This update likely involves behind-the-scenes improvements without altering the displayed study content.SummaryDifference0.1%

Stay in the know with updates to Psilocybin Safety & Efficacy in TRD - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin Safety & Efficacy in TRD - Clinical Trial page.